本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东金城医药集团股份有限公司（以下简称"公司"）第六届董事会第十八 次会议通知于 2025 年 10 月 31 日以邮件通知方式发出。本次董事会会议于 2025 年 11 月 4 日在公司会议室以现场和通讯相结合的方式召开。会议应出席董事 9 名，实际出席会议董事 9 名，其中独立董事王新宇、蔡启孝以及非独立董事李家 全、王辉以通讯方式出席本次会议。独立董事李福利委托独立董事蔡启孝出席本 次会议。 本次会议由董事长赵叶青主持，公司部分高级管理人员列席。会议的召开和 表决程序符合《中华人民共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 证券代码：300233 证券简称：金城医药 公告编号：2025-076 山东金城医药集团股份有限公司 第六届董事会第十八次会议决议公告 表决结果：9 票同意，0 票反对，0 票弃权。 三、备查文件 1、 第六届董事会第十八次会议决议； 2、 《产品权益转让协议》； 3、 《北京金城泰尔制药有限公司拟转让"普罗雌烯阴道用软胶囊生产技术 及上市许 ...

山东金城医药集团股份有限公司（以下简称"公司"）分别于2025年10月23 日、2025年11月4日召开了第六届董事会第十七次会议、第六届董事会第十八次会 议，公司独立董事李福利先生因公务原因连续两次未亲自出席上述董事会会议。 根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作（2025年修订）》第3.3.4规定"连续两次未亲自出席董事会会议的，董事应 当作出书面说明并对外披露。"公司独立董事李福利先生就上述情况作出书面说 明如下：公司于2025年10月23日、2025年11月4日分别召开第六届董事会第十七次 会议、第六届董事会第十八次会议，本人因公务原因，连续两次未能亲自出席董 事会会议。本人已委托其他董事代为表决董事会会议审议的相关议案，受托人按 照授权委托书的授权内容进行表决，本人对董事会会议作出的决议均无异议。 特此公告。 山东金城医药集团股份有限公司董事会 山东金城医药集团股份有限公司 关于董事连续两次未亲自出席董事会会议的说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 2025年11月5日 证券代码：300233 证券 ...

证券代码：300233 证券简称：金城医药 公告编号：2025-075 山东金城医药集团股份有限公司 关于转让药品生产技术及上市许可持有人权益的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、交易概述 （一）基本情况 山东金城医药集团股份有限公司（以下简称"金城医药"或"公司"）之全资子公 司北京金城泰尔制药有限公司（以下简称"金城泰尔"）拟向海默尼（上海）医药科技 有限公司（以下简称"海默尼"）转让所持有的"普罗雌烯阴道用软胶囊生产技术及上 市许可持有人权益"（以下简称"标的产品"或"协议产品"）。 金城泰尔合法持有"普罗雌烯阴道用软胶囊（商品名：朗依更宝芬®）"的药品批准 文号。经交易双方协商一致，标的产品转让的总费用（含税）为人民币伍仟万元整（¥ 5,000万元）。双方确认该金额已充分考虑了标的产品权益的实际价值及市场行情等因 素。 （二）审批情况 公司第六届董事会第十八次会议审议通过了《关于转让药品生产技术及上市许可持 有人权益的议案》。根据《深圳证券交易所创业板股票上市规则》和《公司章程》等相 关规定，本次交易事项在公司董事会决策权限内，无 ...

Core Viewpoint - Jincheng Pharmaceutical is a leading enterprise in the domestic cephalosporin sector, with a comprehensive industry chain advantage, focusing on the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [1] Group 1: Business Performance - For Q3 2025, Jincheng Pharmaceutical reported revenue of 1.932 billion yuan, ranking 34th among 110 companies in the industry, while the industry leader, East China Pharmaceutical, achieved revenue of 32.664 billion yuan [2] - The net profit for the same period was 33.5981 million yuan, placing the company 67th in the industry, with the top performer, Hengrui Medicine, reporting a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Jincheng Pharmaceutical's debt-to-asset ratio was 27.69%, lower than the previous year's 32.87% and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 36.23%, down from 40.13% year-on-year and below the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman, Zhao Yeqing, received a salary of 2.035 million yuan in 2024, an increase of 36,000 yuan from 2023 [4] - The president, Li Jiaquan, earned 1.833 million yuan in 2024, up by 34,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.49% to 25,800, while the average number of circulating A-shares held per shareholder increased by 9.27% to 14,400 [5] - Notable changes among the top ten circulating shareholders include the new entry of Fu Guo Precision Medical Flexible Allocation Mixed A, holding 4.961 million shares, and a reduction in holdings by Hong Kong Central Clearing Limited [5]

Core Viewpoint - The company announced that its subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplemental application of injectable Cefoperazone Sodium and Sulbactam Sodium [2] Group 1 - The approval is significant for the company's product portfolio and may enhance its market position in the pharmaceutical industry [2] - The injectable form of Cefoperazone Sodium and Sulbactam Sodium is expected to meet the growing demand for effective antibiotics in the healthcare sector [2]

证券代码：300233 证券简称：金城医药 公告编号：2025-074 山东金城医药集团股份有限公司 关于子公司收到药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之控股子公司广东金城金素制药有限公司 （以下简称"金城金素"）于近日收到国家药品监督管理局下发的注射用头孢哌 酮钠舒巴坦钠《药品补充申请批准通知书》，现将主要内容公告如下： 二、药品相关信息 头孢哌酮钠舒巴坦钠适用于治疗由敏感菌所引起的上、下呼吸道感染；上、 下泌尿道感染；腹膜炎、胆囊炎、胆管炎和其他腹腔内感染；败血症；脑膜炎； 皮肤和软组织感染；骨骼和关节感染；盆腔炎、子宫内膜炎、淋病和其他生殖道 感染等。 三、 对公司的影响及风险提示 本次金城金素注射用头孢哌酮钠舒巴坦钠获得药品补充申请批准通知书，对 公司产品品质的提升具有积极意义。由于药品销售受国家政策、市场环境等不确 产品 名称 剂型 注册 分类 规格 包装 规格 原药品 批准文号 上市许可 持有人 审批结论 注射 用头 孢哌 酮钠 舒巴 坦钠 注 射 剂 化学 药品 1.0g 1 ...

Group 1 - Chuanfa Longmang's wholly-owned subsidiary plans to invest 660 million yuan to establish a joint venture for a 175,000 tons/year high-pressure lithium iron phosphate project in Sichuan Mianzhu, with a total investment of 1.961 billion yuan [1] - The joint venture will be co-owned by Jiangxi Shenghua New Materials (51%) and Deyang Chuanfa Longmang (49%) [1] - Chuanfa Longmang specializes in the production and sales of various phosphate products, including lithium iron phosphate [1] Group 2 - Sino Medical's COMETIU self-expanding intracranial drug-coated stent system registration application was not approved by the National Medical Products Administration [2] - Sino Medical focuses on the research, development, production, and sales of high-end interventional medical devices [3] Group 3 - Jincheng Pharmaceutical's subsidiaries have been selected for the 11th batch of national drug centralized procurement [3] - Jincheng Pharmaceutical is engaged in the research, development, production, and sales of pharmaceutical intermediates and formulations [3] Group 4 - Zhongke Lanyun reported a 4.29% increase in revenue to 1.302 billion yuan and a 2.17% increase in net profit to 211 million yuan for the first three quarters [4] - The company specializes in wireless audio SoC chip research, design, and sales [5] Group 5 - Dabo Medical achieved a 22.69% increase in revenue to 1.876 billion yuan and a 77.03% increase in net profit to 425 million yuan for the first three quarters [6] - Dabo Medical focuses on the production, research, and sales of high-value medical consumables [7] Group 6 - Dayang Electric reported a 3.81% increase in revenue to 9.180 billion yuan and a 25.95% increase in net profit to 845 million yuan for the first three quarters [8][9] - The company operates in the electric motor sector, focusing on building and home appliance motors and automotive components [9] Group 7 - Fudan Microelectronics reported a 12.70% increase in revenue to 3.024 billion yuan but a 22.69% decrease in net profit to 330 million yuan for the first three quarters [10][11] - The company specializes in the design, development, and testing of large-scale integrated circuits [11] Group 8 - Shaanxi Energy reported a 2.83% decrease in revenue to 16.359 billion yuan and a 3.23% decrease in net profit to 2.417 billion yuan for the first three quarters [12][13] - The company is involved in thermal power generation and coal production and sales [13] Group 9 - Runhe Software reported a 12.86% increase in revenue to 2.719 billion yuan but a 29.01% decrease in net profit to 78.57 million yuan for the first three quarters [14][15] - The company focuses on financial technology, smart IoT, and smart energy [15] Group 10 - Shenzhen Gas reported an 8.63% increase in revenue to 22.528 billion yuan but a 13.08% decrease in net profit to 918 million yuan for the first three quarters [16][17] - The company specializes in urban gas supply and comprehensive energy services [17] Group 11 - Light Media reported a 150.81% increase in revenue to 3.616 billion yuan and a 406.78% increase in net profit to 2.336 billion yuan for the first three quarters [18][19] - The company is engaged in the investment, production, and distribution of film projects [19] Group 12 - Dazhong Mining's subsidiary obtained a mining license for the Hunan Jijiao Mountain lithium mine, with a resource amount of 490 million tons, equivalent to approximately 3.2443 million tons of lithium carbonate [19] - The company specializes in iron ore mining and production [19] Group 13 - Yirui Technology reported a 14.22% increase in revenue to 1.549 billion yuan and a 20.61% increase in net profit to 471 million yuan for the first three quarters [20] - The company focuses on the research, production, and sales of digital X-ray detectors and related solutions [20] Group 14 - TCL Zhonghuan reported a 4.48% decrease in revenue to 121.572 billion yuan and a net loss of 5.777 billion yuan for the first three quarters [21][22] - The company specializes in the research, production, and sales of photovoltaic silicon wafers, cells, and modules [22] Group 15 - Huangshan Tourism reported an 8.75% increase in revenue to 1.535 billion yuan but an 11.02% decrease in net profit to 253 million yuan for the first three quarters [23][24] - The company provides tourism and leisure services [24] Group 16 - Mountain Outside Mountain reported a 39.79% increase in revenue to 584 million yuan and a 68.68% increase in net profit to 105 million yuan for the first three quarters [25][26] - The company specializes in the research, production, and sales of blood purification equipment and services [26] Group 17 - Huajin Capital reported a 16.36% increase in revenue to 349 million yuan and a 185.62% increase in net profit to 104 million yuan for the first three quarters [27] - The company focuses on investment management and electronic device manufacturing [27] Group 18 - Datang Power reported a 1.82% decrease in revenue to 89.345 billion yuan but a 51.48% increase in net profit to 6.712 billion yuan for the first three quarters [28][29] - The company primarily engages in thermal power generation [29] Group 19 - Datang Power announced the acquisition of a 50% stake in Anhui Electric Power for 1 yuan, which will result in full ownership of Anhui Electric Power [30] - The company focuses on thermal power generation [30] Group 20 - Kairun Co. reported a 22.94% increase in revenue to 3.719 billion yuan but a 13.38% decrease in net profit to 278 million yuan for the first three quarters [31] - The company specializes in the research, design, production, and sales of leisure bags and related products [31] Group 21 - Dafu Technology reported a 1.95% increase in revenue to 1.764 billion yuan but a net loss of 170 million yuan for the first three quarters [32] - The company focuses on the research, production, and sales of RF products and automotive components [32] Group 22 - Dafu Technology plans to publicly transfer 49% of its stake in Dasheng Graphite [34] - The company specializes in the research, production, and sales of RF products and automotive components [34]

Core Viewpoint - Jincheng Pharmaceutical announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., and its holding subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., participated in the 11th national centralized procurement organized by the Joint Procurement Office, with plans to be selected for the procurement of Ribavirin tablets and Cefazolin sodium for injection [1] Group 1 - Jincheng Tail and Jincheng Jinsu are involved in the national drug centralized procurement bidding process [1] - The targeted products for procurement include Ribavirin tablets and Cefazolin sodium for injection [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiaries participated in the 11th national centralized procurement of drugs, with two products expected to be selected for procurement [1] Group 1: Company Participation - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., and its controlling subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., took part in the bidding for the national centralized drug procurement organized by the Joint Procurement Office [1] Group 2: Products Involved - The products involved in the bidding include Jincheng Tail's Ribavirin tablets and Jincheng Jinsu's injectable Cefazolin sodium, which are anticipated to be selected in this centralized procurement [1]

Core Viewpoint - Jincheng Pharmaceutical announced participation in the 11th national centralized drug procurement organized by the Joint Procurement Office, with two of its products expected to be selected for procurement [1] Company Summary - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., and its controlling subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., are involved in the bidding process for the centralized procurement [1] - The two products involved are Jincheng Tail's Ribavirin Tablets and Jincheng Jinsu's Injectable Cefazolin Sodium [1] - The company's revenue composition for 2024 is projected to be 100% from the pharmaceutical manufacturing industry [1] - As of the announcement, Jincheng Pharmaceutical has a market capitalization of 6.6 billion yuan [1]